Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Finished Goods (2019 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Finished Goods for 7 consecutive years, with $30.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods fell 4.13% to $30.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $30.6 million, a 4.13% decrease, with the full-year FY2024 number at $29.2 million, up 4.08% from a year prior.
  • Finished Goods was $30.6 million for Q3 2025 at Xtant Medical Holdings, down from $31.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $31.9 million in Q3 2024 to a low of $10.6 million in Q2 2022.
  • A 5-year average of $20.7 million and a median of $16.3 million in 2021 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: crashed 31.46% in 2022, then surged 158.62% in 2024.
  • Xtant Medical Holdings' Finished Goods stood at $11.8 million in 2021, then dropped by 7.67% to $10.9 million in 2022, then surged by 158.35% to $28.1 million in 2023, then grew by 4.08% to $29.2 million in 2024, then grew by 4.72% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Finished Goods are $30.6 million (Q3 2025), $31.2 million (Q2 2025), and $30.5 million (Q1 2025).